PDB38 REAL-WORLD COMPARISON OF HOSPITALIZATION COSTS FOR HEART FAILURE IN T2DM PATIENTS WITH CARDIOVASCULAR DISEASE TREATED WITH CANAGLIFLOZIN VERSUS OTHER ANTIHYPERGLYCEMIC AGENTS
May 1, 2019, 00:00 AM
10.1016/j.jval.2019.04.588
https://www.valueinhealthjournal.com/article/S1098-3015(19)30780-6/fulltext
Section Title :
Section Order :
10210
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30780-6&doi=10.1016/j.jval.2019.04.588